我們已在上線！進一步了解

Opko Health

OPK

市值 US$11.4億

1.53 USD

-0.08

4.97%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

1.52

-0.01

0.65%

1天

-4.97%

5天

10.87%

1個月

-4.97%

3個月

28.57%

6個月

26.45%

今年迄今

20.47%

1年

2%

5年

-58.65%

10年

-83.57%

關於： OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

員工： 2,275

醫療保健診斷與研究

新聞

正面

中性

負面

市場情緒 3個月

正面 50%

中性 42.3%

負面 7.7%

Zacks Investment Research

OPKO Health to Sell Select BioReference Assets to Labcorp for $722M

OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its biopharma focus and expand access to the 4Kscore Test.

OPKO Health to Sell Select BioReference Assets to Labcorp for $722M

OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal

Labcorp Holdings Inc. (NYSE:LH) stock traded higher Thursday after the company agreed to acquire select assets of BioReference Health from OPKO Health Inc. (NASDAQ:OPK) in a deal worth up to $872 million.

OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal

Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday

U.S. stocks were mixed, with the Dow Jones index gaining around 200 points on Thursday.

Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla.

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Zacks Investment Research

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

Zacks Investment Research

OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?

OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.

OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?

OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months

OPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.

OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months

OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference

MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that Elias A.

OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference

Zacks Investment Research

Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?

Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?

Zacks Investment Research

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

查看新聞排名

價格圖表採用Lightweight Charts™實作